No Data
No Data
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Treace Medical Concepts (TMCI) and Veeva Systems (VEEV)
Treace Medical Concepts(TMCI.US) Director Buys US$130.06K in Common Stock
$Treace Medical Concepts(TMCI.US)$ Director TREACE JAMES T purchased 25,000 shares of common stock on May 29, 2024 at an average price of $5.2025 for a total value of $130.06K.Source: Announcement Wha
Treace Medical Concepts(TMCI.US) Director Buys US$253.47K in Common Stock
$Treace Medical Concepts(TMCI.US)$ Director TREACE JAMES T purchased 50,000 shares of common stock on May 28, 2024 at an average price of $5.0695 for a total value of $253.47K.Source: Announcement Wha
Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing
James T Treace, Director, on May 28, 2024, executed a purchase for 50,000 shares in Treace Medical Concepts (TMCI) for $253,475. Following the Form 4 filing with the SEC, Treace has control over a tot
Treace Medical Concepts(TMCI.US) Director Buys US$93,501 in Common Stock
$Treace Medical Concepts(TMCI.US)$ Director MOTT RICHARD W purchased 18,000 shares of common stock on May 24, 2024 at an average price of $5.1945 for a total value of $93,501.Source: Announcement What
Treace to Present at Truist Securities MedTech Conference
PONTE VEDRA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ:TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions
No Data